Louisa Taylor
Y-box binding protein-1: A neglected target in pediatric brain tumors?
Taylor, Louisa; Kerr, Ian D.; Coyle, Beth
Authors
Dr IAN KERR ian.kerr@nottingham.ac.uk
ASSOCIATE PROFESSOR
Professor BETH COYLE BETH.COYLE@NOTTINGHAM.AC.UK
PROFESSOR OF BRAIN TUMOUR MICROENVIRONMENT
Abstract
© 2020 American Association for Cancer Research. Brain and central nervous system tumors represent the most common childhood solid tumors. Comprising 21% of all pediatric cancers, they remain the leading cause of cancer-related mortality and morbidity in childhood. Due to advances in neurosurgical technique, radiotherapy and the use of combination therapy, survival rates have generally increased. However, by cause of the lesion itself, its surgical removal and subsequent treatment, survivors are at high risk of long-term neurocognitive sequelae and secondary cancer. Clearly, improvements in diagnosis and treatment are needed. Accordingly, current treatment is evolving away from conventional, uniform therapy and towards risk-stratified regimens and molecularly-targeted therapies, with the aim of diminishing adverse side effects while minimizing the risk of disease recurrence. The multifunctional oncoprotein Y-box binding protein 1 (YB-1) may serve as one such molecular target. Increased YB-1 levels have been reported in a number of pediatric brain tumors, where YB-1 appears to facilitate the advancement of malignant phenotypes. These include proliferation, invasion, and resistance to therapy, as well as the maintenance of brain tumor-initiating cells. Here we evaluate the current literature and show how YB-1 modulates signaling pathways driving each of these phenotypes. We also review the regulation of YB-1 at a transcriptional, translational, posttranslational and subcellular level and argue that there is strong and sufficient evidence to support the development of YB-1 as a biomarker and future therapeutic target in childhood brain tumors.
Citation
Taylor, L., Kerr, I. D., & Coyle, B. (2021). Y-box binding protein-1: A neglected target in pediatric brain tumors?. Molecular Cancer Research, 19(3), 375-387. https://doi.org/10.1158/1541-7786.MCR-20-0655
Journal Article Type | Article |
---|---|
Acceptance Date | Nov 20, 2020 |
Online Publication Date | Nov 25, 2020 |
Publication Date | Mar 1, 2021 |
Deposit Date | Nov 30, 2020 |
Publicly Available Date | Nov 26, 2021 |
Journal | Molecular Cancer Research |
Print ISSN | 1541-7786 |
Electronic ISSN | 1557-3125 |
Publisher | American Association for Cancer Research |
Peer Reviewed | Peer Reviewed |
Volume | 19 |
Issue | 3 |
Pages | 375-387 |
DOI | https://doi.org/10.1158/1541-7786.MCR-20-0655 |
Keywords | Cancer Research; Oncology; Molecular Biology |
Public URL | https://nottingham-repository.worktribe.com/output/5088621 |
Publisher URL | https://mcr.aacrjournals.org/content/early/2020/11/25/1541-7786.MCR-20-0655 |
Files
Y-box Binding Protein-1
(1.8 Mb)
PDF
You might also like
A time-resolved Förster resonance energy transfer assay to investigate inhibitor binding to ABCG2
(2023)
Preprint / Working Paper
Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature
(2023)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search